2024-05-01 |
2024-05-01 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-2.7%
3,30
100 000
USD
|
1 000
-2.7%
|
3,30
|
100 000
USD
|
|
2024-05-01 |
2024-04-30 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-1.6%
3,12
100 000
USD
|
1 000
-1.6%
|
3,12
|
100 000
USD
|
|
2024-05-01 |
2024-04-29 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-0.5%
3,25
100 000
USD
|
1 000
-0.5%
|
3,25
|
100 000
USD
|
|
2024-04-24 |
2024-04-24 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-0.6%
3,50
100 000
USD
|
1 000
-0.6%
|
3,50
|
100 000
USD
|
|
2024-04-24 |
2024-04-23 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-1.7%
3,49
100 000
USD
|
1 000
-1.7%
|
3,49
|
100 000
USD
|
|
2024-04-24 |
2024-04-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 000
-1.1%
3,53
100 000
USD
|
1 000
-1.1%
|
3,53
|
100 000
USD
|
|
2024-04-18 |
2024-04-17 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
22 737
-1.7%
3,71
84 425
USD
|
22 737
-1.7%
|
3,71
|
84 425
USD
|
|
2024-04-18 |
2024-04-16 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
48 683
-3.5%
3,53
171 802
USD
|
48 683
-3.5%
|
3,53
|
171 802
USD
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
5 803
-100.0%
14,18
82 265
USD
|
5 803
-100.0%
|
14,18
|
82 265
USD
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
26 732
-82.2%
12,94
345 915
USD
|
26 732
-82.2%
|
12,94
|
345 915
USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Thomas John
Administrateur non-exécutif
|
1 927
-0.4%
13,93
26 839
USD
|
1 927
-0.4%
|
13,93
|
26 839
USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Thomas John
Administrateur non-exécutif
|
7 073
-1.5%
13,23
93 548
USD
|
7 073
-1.5%
|
13,23
|
93 548
USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Tyree James L
Administrateur non-exécutif
|
3 347
-49.2%
13,73
45 963
USD
|
3 347
-49.2%
|
13,73
|
45 963
USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Tyree James L
Administrateur non-exécutif
|
5 653
-45.4%
12,91
73 006
USD
|
5 653
-45.4%
|
12,91
|
73 006
USD
|
|
2023-12-08 |
2023-12-07 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
36 800
-53.1%
11,85
435 995
USD
|
36 800
-53.1%
|
11,85
|
435 995
USD
|
|
2023-11-22 |
2023-11-21 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
18 665
-21.2%
10,26
191 555
USD
|
18 665
-21.2%
|
10,26
|
191 555
USD
|
|
2023-11-21 |
2023-11-20 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
14 594
-14.2%
11,26
164 261
USD
|
14 594
-14.2%
|
11,26
|
164 261
USD
|
|
2023-11-21 |
2023-11-17 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
3 541
-3.3%
13,04
46 170
USD
|
3 541
-3.3%
|
13,04
|
46 170
USD
|
|
2023-10-26 |
2023-10-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
5 704
-0.4%
19,40
110 638
USD
|
5 704
-0.4%
|
19,40
|
110 638
USD
|
|
2023-10-25 |
2023-10-24 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
5 200
-4.7%
19,11
99 351
USD
|
5 200
-4.7%
|
19,11
|
99 351
USD
|
|
2023-10-25 |
2023-10-23 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
49 987
-3.5%
19,97
998 365
USD
|
49 987
-3.5%
|
19,97
|
998 365
USD
|
|
2023-10-16 |
2023-10-16 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
881
-0.2%
21,30
18 769
USD
|
881
-0.2%
|
21,30
|
18 769
USD
|
|
2023-10-16 |
2023-10-16 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
2 452
-0.5%
20,50
50 269
USD
|
2 452
-0.5%
|
20,50
|
50 269
USD
|
|
2023-10-11 |
2023-10-10 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
400
-0.4%
22,91
9 162
USD
|
400
-0.4%
|
22,91
|
9 162
USD
|
|
2023-10-11 |
2023-10-10 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
4 800
-4.3%
21,94
105 300
USD
|
4 800
-4.3%
|
21,94
|
105 300
USD
|
|
2023-10-10 |
2023-10-05 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
985
-0.1%
25,47
25 090
USD
|
985
-0.1%
|
25,47
|
25 090
USD
|
|
2023-10-10 |
2023-10-05 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 266
-0.9%
24,89
330 139
USD
|
13 266
-0.9%
|
24,89
|
330 139
USD
|
|
2023-10-04 |
2023-10-03 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
75 690
-5.0%
25,49
1 929 225
USD
|
75 690
-5.0%
|
25,49
|
1 929 225
USD
|
|
2023-09-29 |
2023-09-28 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 289
-0.2%
24,12
55 211
USD
|
2 289
-0.2%
|
24,12
|
55 211
USD
|
|
2023-09-29 |
2023-09-27 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
11 257
-0.7%
24,47
275 459
USD
|
11 257
-0.7%
|
24,47
|
275 459
USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
2 203
-2.0%
24,46
53 890
USD
|
2 203
-2.0%
|
24,46
|
53 890
USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
1 114
-1.0%
23,51
26 195
USD
|
1 114
-1.0%
|
23,51
|
26 195
USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
1 883
-1.7%
22,54
42 442
USD
|
1 883
-1.7%
|
22,54
|
42 442
USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
9 600
-0.6%
24,51
235 296
USD
|
9 600
-0.6%
|
24,51
|
235 296
USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
12 740
-0.8%
24,03
306 142
USD
|
12 740
-0.8%
|
24,03
|
306 142
USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
7 465
-0.5%
22,47
167 739
USD
|
7 465
-0.5%
|
22,47
|
167 739
USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 100
-0.1%
27,81
30 591
USD
|
1 100
-0.1%
|
27,81
|
30 591
USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 900
-0.1%
26,60
50 540
USD
|
1 900
-0.1%
|
26,60
|
50 540
USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
5 511
-0.4%
25,75
141 908
USD
|
5 511
-0.4%
|
25,75
|
141 908
USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
3 947
-0.3%
24,82
97 965
USD
|
3 947
-0.3%
|
24,82
|
97 965
USD
|
|
2023-09-25 |
2023-09-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 621
-0.3%
27,76
128 270
USD
|
4 621
-0.3%
|
27,76
|
128 270
USD
|
|
2023-09-25 |
2023-09-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 421
-0.3%
26,88
118 853
USD
|
4 421
-0.3%
|
26,88
|
118 853
USD
|
|
2023-09-25 |
2023-09-21 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 678
-0.3%
28,82
134 815
USD
|
4 678
-0.3%
|
28,82
|
134 815
USD
|
|
2023-09-25 |
2023-09-21 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 871
-0.2%
27,89
80 063
USD
|
2 871
-0.2%
|
27,89
|
80 063
USD
|
|
2023-09-21 |
2023-09-20 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
6 000
-5.4%
27,96
167 786
USD
|
6 000
-5.4%
|
27,96
|
167 786
USD
|
|
2023-09-21 |
2023-09-20 |
VP
Vente planifiée
|
Ryder Sean
General Counsel
Dirigeant
|
10 000
-94.6%
30,00
300 000
USD
|
10 000
-94.6%
|
30,00
|
300 000
USD
|
|
2023-09-20 |
2023-09-19 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
8 247
-100.0%
27,16
223 979
USD
|
8 247
-100.0%
|
27,16
|
223 979
USD
|
|
2023-09-20 |
2023-09-19 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
23 920
-74.4%
26,21
626 962
USD
|
23 920
-74.4%
|
26,21
|
626 962
USD
|
|
2023-09-20 |
2023-09-18 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 927
-36.9%
24,17
70 754
USD
|
2 927
-36.9%
|
24,17
|
70 754
USD
|
|
2023-09-20 |
2023-09-18 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
27 365
-77.5%
23,20
634 895
USD
|
27 365
-77.5%
|
23,20
|
634 895
USD
|
|
2023-09-18 |
2023-09-18 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
3 334
-0.7%
24,99
83 317
USD
|
3 334
-0.7%
|
24,99
|
83 317
USD
|
|
2023-09-18 |
2023-09-15 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
1 088
-0.2%
22,38
24 354
USD
|
1 088
-0.2%
|
22,38
|
24 354
USD
|
|
2023-09-18 |
2023-09-15 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
2 245
-0.5%
21,67
48 642
USD
|
2 245
-0.5%
|
21,67
|
48 642
USD
|
|
2023-09-18 |
2023-09-15 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
4 675
-4.2%
22,29
104 212
USD
|
4 675
-4.2%
|
22,29
|
104 212
USD
|
|
2023-09-18 |
2023-09-15 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
5 725
-4.9%
21,56
123 418
USD
|
5 725
-4.9%
|
21,56
|
123 418
USD
|
|
2023-09-15 |
2023-09-14 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 871
-28.2%
22,31
309 522
USD
|
13 871
-28.2%
|
22,31
|
309 522
USD
|
|
2023-09-15 |
2023-09-14 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
11 405
-18.8%
21,77
248 285
USD
|
11 405
-18.8%
|
21,77
|
248 285
USD
|
|
2023-09-15 |
2023-09-13 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
29 800
-21.9%
21,14
629 927
USD
|
29 800
-21.9%
|
21,14
|
629 927
USD
|
|
2023-09-15 |
2023-09-13 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
3 315
-5.2%
22,31
73 961
USD
|
3 315
-5.2%
|
22,31
|
73 961
USD
|
|
2023-09-15 |
2023-09-13 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
15 717
-19.7%
21,26
334 132
USD
|
15 717
-19.7%
|
21,26
|
334 132
USD
|
|
2023-09-14 |
2023-09-13 |
V
Vente
|
Smither John W
Administrateur non-exécutif
|
900
-11.5%
20,78
18 702
USD
|
900
-11.5%
|
20,78
|
18 702
USD
|
|
2023-09-13 |
2023-09-12 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 727
-14.7%
22,51
308 936
USD
|
13 727
-14.7%
|
22,51
|
308 936
USD
|
|
2023-09-13 |
2023-09-12 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
6 538
-6.5%
21,75
142 231
USD
|
6 538
-6.5%
|
21,75
|
142 231
USD
|
|
2023-09-13 |
2023-09-11 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
23 020
-18.7%
22,55
519 156
USD
|
23 020
-18.7%
|
22,55
|
519 156
USD
|
|
2023-09-13 |
2023-09-11 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
9 331
-7.1%
21,39
199 545
USD
|
9 331
-7.1%
|
21,39
|
199 545
USD
|
|
2023-09-11 |
2023-09-08 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 636
-2.0%
24,19
63 752
USD
|
2 636
-2.0%
|
24,19
|
63 752
USD
|
|
2023-09-11 |
2023-09-08 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
8 523
-5.9%
23,49
200 169
USD
|
8 523
-5.9%
|
23,49
|
200 169
USD
|
|
2023-09-11 |
2023-09-08 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 672
-8.7%
22,78
311 411
USD
|
13 672
-8.7%
|
22,78
|
311 411
USD
|
|
2023-09-11 |
2023-09-07 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 508
-1.6%
25,34
63 551
USD
|
2 508
-1.6%
|
25,34
|
63 551
USD
|
|
2023-09-11 |
2023-09-07 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
9 938
-5.9%
24,12
239 716
USD
|
9 938
-5.9%
|
24,12
|
239 716
USD
|
|
2023-08-30 |
2023-08-30 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
19 800
-12.7%
24,70
489 060
USD
|
19 800
-12.7%
|
24,70
|
489 060
USD
|
|
2023-08-22 |
2023-08-18 |
V
Vente
|
Zindrick Thomas
President and CEO
Administrateur exécutif
|
8 349
-36.3%
23,73
198 122
USD
|
8 349
-36.3%
|
23,73
|
198 122
USD
|
|
2023-08-22 |
2023-08-18 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
3 265
-2.1%
23,73
77 478
USD
|
3 265
-2.1%
|
23,73
|
77 478
USD
|
|
2023-08-22 |
2023-08-18 |
V
Vente
|
Smalling Ralph
Head of Regulatory
Dirigeant
|
935
-31.2%
23,73
22 188
USD
|
935
-31.2%
|
23,73
|
22 188
USD
|
|
2023-08-22 |
2023-08-18 |
V
Vente
|
Ryder Sean
General Counsel
Dirigeant
|
328
-36.4%
23,73
7 783
USD
|
328
-36.4%
|
23,73
|
7 783
USD
|
|